Literature DB >> 22225615

Fibroblast progenitor cells are recruited into the myocardium prior to the development of myocardial fibrosis.

Mryanda Sopel1, Alec Falkenham, Adam Oxner, Irene Ma, Timothy D G Lee, Jean-Francois Légaré.   

Abstract

Using an established model of myocardial hypertrophy and fibrosis after angiotensin II (AngII) infusion, our aim was to characterize the early cellular element involved in the development of myocardial fibrosis in detail. Male Lewis rats were infused with saline or AngII (0.7 mg/kg per day) for up to seven days. Collagen deposition and cellular infiltration were identified by histology stains. Infiltrating cells were grown in vitro and examined by flow cytometry and immunostaining. Chemokine expression was measured using qRT-PCR. AngII infusion resulted in multifocal myocardial cellular infiltration (peak at three days) that preceded collagen deposition. Monocyte chemotactic protein (MCP)-1 transcripts peaked after one day of AngII exposure. Using a triple-labelling technique, the infiltrating cells were found to express markers of leucocyte (ED1(+)), mesenchymal [α-smooth muscle actin (SMA)(+)] and haematopeotic progenitor cells (CD133(+)) suggesting a fibroblast progenitor phenotype. In vitro, ED1(+)/SMA(+)/CD133(+) cells were isolated and grown from AngII-exposed animals. Comparatively few cells were cultured from untreated control hearts, and they were found to be ED1(-)/SMA(+)/CD133(-). We provide evidence that myocardial ECM deposition is preceded by infiltration into the myocardium by cells that express a combination of haematopoietic (ED1, CD133) and mesenchymal (SMA) cell markers, which is a characteristic of the phenotype of fibroblast precursor cells, termed fibrocytes. This suggests that fibrocytes rather than (as is often presumed) leucocytes may have effector functions in the initiation of myocardial fibrosis.
© 2012 The Authors. International Journal of Experimental Pathology © 2012 International Journal of Experimental Pathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22225615      PMCID: PMC3385703          DOI: 10.1111/j.1365-2613.2011.00797.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  31 in total

1.  Subpopulations of mouse blood monocytes differ in maturation stage and inflammatory response.

Authors:  Cord Sunderkötter; Tatjana Nikolic; Marilyn J Dillon; Nico Van Rooijen; Martin Stehling; Douglas A Drevets; Pieter J M Leenen
Journal:  J Immunol       Date:  2004-04-01       Impact factor: 5.422

2.  Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration.

Authors:  G Fujisawa; R Dilley; M J Fullerton; J W Funder
Journal:  Endocrinology       Date:  2001-08       Impact factor: 4.736

3.  Myocardial fibrosis in response to Angiotensin II is preceded by the recruitment of mesenchymal progenitor cells.

Authors:  Mryanda J Sopel; Nicole L Rosin; Timothy D G Lee; Jean-Francois Légaré
Journal:  Lab Invest       Date:  2010-11-29       Impact factor: 5.662

Review 4.  Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases.

Authors:  S Kim; H Iwao
Journal:  Pharmacol Rev       Date:  2000-03       Impact factor: 25.468

Review 5.  Vascular inflammation and the renin-angiotensin system.

Authors:  Allan R Brasier; Adrian Recinos; Mohsen S Eledrisi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-08-01       Impact factor: 8.311

Review 6.  Liver fibrosis: from the bench to clinical targets.

Authors:  M Pinzani; K Rombouts
Journal:  Dig Liver Dis       Date:  2004-04       Impact factor: 4.088

7.  Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling.

Authors:  Qingwei Zhao; Minako Ishibashi; Ken-ichi Hiasa; Chunyan Tan; Akira Takeshita; Kensuke Egashira
Journal:  Hypertension       Date:  2004-07-19       Impact factor: 10.190

8.  Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis.

Authors:  Roderick J Phillips; Marie D Burdick; Kurt Hong; Marin A Lutz; Lynne A Murray; Ying Ying Xue; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 9.  Circulating fibrocytes: collagen-secreting cells of the peripheral blood.

Authors:  Timothy E Quan; Shawn Cowper; Sou-Pan Wu; Linda K Bockenstedt; Richard Bucala
Journal:  Int J Biochem Cell Biol       Date:  2004-04       Impact factor: 5.085

10.  NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy.

Authors:  Jianhua Liu; Fang Yang; Xiao-Ping Yang; Michelle Jankowski; Patrick J Pagano
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-03-13       Impact factor: 8.311

View more
  12 in total

1.  CXCR6 plays a critical role in angiotensin II-induced renal injury and fibrosis.

Authors:  Yunfeng Xia; Xiaogao Jin; Jingyin Yan; Mark L Entman; Yanlin Wang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-05-22       Impact factor: 8.311

Review 2.  Targeting cardiac fibroblasts to treat fibrosis of the heart: focus on HDACs.

Authors:  Katherine B Schuetze; Timothy A McKinsey; Carlin S Long
Journal:  J Mol Cell Cardiol       Date:  2014-03-11       Impact factor: 5.000

Review 3.  Entanglement of GSK-3β, β-catenin and TGF-β1 signaling network to regulate myocardial fibrosis.

Authors:  Yuanjun Guo; Manisha Gupte; Prachi Umbarkar; Anand Prakash Singh; Jennifer Y Sui; Thomas Force; Hind Lal
Journal:  J Mol Cell Cardiol       Date:  2017-07-27       Impact factor: 5.000

Review 4.  Regeneration in heart disease-Is ECM the key?

Authors:  Ahmad F Bayomy; Michael Bauer; Yiling Qiu; Ronglih Liao
Journal:  Life Sci       Date:  2012-09-12       Impact factor: 5.037

5.  Fibrocyte migration, differentiation and apoptosis during the corneal wound healing response to injury.

Authors:  Luciana Lassance; Gustavo K Marino; Carla S Medeiros; Shanmugapriya Thangavadivel; Steven E Wilson
Journal:  Exp Eye Res       Date:  2018-02-24       Impact factor: 3.467

6.  Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.

Authors:  Sarah M Williams; Lucy Golden-Mason; Bradley S Ferguson; Katherine B Schuetze; Maria A Cavasin; Kim Demos-Davies; Michael E Yeager; Kurt R Stenmark; Timothy A McKinsey
Journal:  J Mol Cell Cardiol       Date:  2013-12-26       Impact factor: 5.000

7.  Treatment with activated protein C (aPC) is protective during the development of myocardial fibrosis: an angiotensin II infusion model in mice.

Authors:  Mryanda J Sopel; Nicole L Rosin; Alec G Falkenham; Michael Bezuhly; Charles T Esmon; Timothy D G Lee; Robert S Liwski; Jean-Francois Légaré
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 8.  Chemokines and Heart Disease: A Network Connecting Cardiovascular Biology to Immune and Autonomic Nervous Systems.

Authors:  Veronica Dusi; Alice Ghidoni; Alice Ravera; Gaetano M De Ferrari; Laura Calvillo
Journal:  Mediators Inflamm       Date:  2016-05-03       Impact factor: 4.711

9.  Antibody therapy can enhance AngiotensinII-induced myocardial fibrosis.

Authors:  Nicole L Rosin; Alison J Gareau; Devin Betsch; Alec Falkenham; Mryanda J Sopel; Timothy Dg Lee; Jean-Francois Légaré
Journal:  Fibrogenesis Tissue Repair       Date:  2014-04-10

Review 10.  Role of Circulating Fibrocytes in Cardiac Fibrosis.

Authors:  Rong-Jie Lin; Zi-Zhuo Su; Shu-Min Liang; Yu-Yang Chen; Xiao-Rong Shu; Ru-Qiong Nie; Jing-Feng Wang; Shuang-Lun Xie
Journal:  Chin Med J (Engl)       Date:  2016-02-05       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.